KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Capital Expenditures (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Capital Expenditures for 14 consecutive years, with $427000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 100.47% to $427000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 84.55% increase, with the full-year FY2025 number at $1.3 million, up 84.55% from a year prior.
  • Capital Expenditures was $427000.0 for Q4 2025 at Supernus Pharmaceuticals, up from $129000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $549000.0 in Q1 2022 to a low of -$158000.0 in Q3 2022.
  • A 4-year average of $189125.0 and a median of $179500.0 in 2023 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: tumbled 260.0% in 2023, then skyrocketed 691.67% in 2024.
  • Supernus Pharmaceuticals' Capital Expenditures stood at -$10000.0 in 2022, then crashed by 260.0% to -$36000.0 in 2023, then surged by 691.67% to $213000.0 in 2024, then skyrocketed by 100.47% to $427000.0 in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Capital Expenditures are $427000.0 (Q4 2025), $129000.0 (Q3 2025), and $455000.0 (Q2 2025).